148 related articles for article (PubMed ID: 36985481)
1. Design, Synthesis and Biological Evaluation of Quinoline-8-Sulfonamides as Inhibitors of the Tumor Cell-Specific M2 Isoform of Pyruvate Kinase: Preliminary Study.
Marciniec K; Rzepka Z; Chrobak E; Boryczka S; Latocha M; Wrześniok D; Beberok A
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985481
[TBL] [Abstract][Full Text] [Related]
2. New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds.
Zhang Y; Liu B; Wu X; Li R; Ning X; Liu Y; Liu Z; Ge Z; Li R; Yin Y
Bioorg Med Chem; 2015 Aug; 23(15):4815-4823. PubMed ID: 26081759
[TBL] [Abstract][Full Text] [Related]
3. Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC).
Li RZ; Fan XX; Shi DF; Zhu GY; Wang YW; Luo LX; Pan HD; Yao XJ; Leung EL; Liu L
Chem Biol Drug Des; 2018 Nov; 92(5):1851-1858. PubMed ID: 29931766
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
Ning X; Qi H; Li R; Li Y; Jin Y; McNutt MA; Liu J; Yin Y
Eur J Med Chem; 2017 Sep; 138():343-352. PubMed ID: 28688274
[TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy.
Adnan M; Shamsi A; Elasbali AM; Siddiqui AJ; Patel M; Alshammari N; Alharethi SH; Alhassan HH; Bardakci F; Hassan MI
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361954
[TBL] [Abstract][Full Text] [Related]
6. 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
Walsh MJ; Brimacombe KR; Veith H; Bougie JM; Daniel T; Leister W; Cantley LC; Israelsen WJ; Vander Heiden MG; Shen M; Auld DS; Thomas CJ; Boxer MB
Bioorg Med Chem Lett; 2011 Nov; 21(21):6322-7. PubMed ID: 21958545
[TBL] [Abstract][Full Text] [Related]
7. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma.
Mukherjee J; Phillips JJ; Zheng S; Wiencke J; Ronen SM; Pieper RO
PLoS One; 2013; 8(2):e57610. PubMed ID: 23451252
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of the M2 Isoform of Pyruvate Kinase (PKM2) with shRNA Enhances the Effect of Docetaxel in Human NSCLC Cell Lines In Vitro.
Yuan S; Qiao T; Zhuang X; Chen W; Xing N; Zhang Q
Yonsei Med J; 2016 Nov; 57(6):1312-23. PubMed ID: 27593857
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effects of novel alkannin derivatives with potent selectivity on comprehensive analysis.
Dai ZQ; Gao F; Zhang ZJ; Lu MJ; Luo YJ; Zhang T; Shang BX; Gu YH; Zeng Q; Gao S; Guo ZQ; Xu B; Lei HM
Phytomedicine; 2023 Aug; 117():154912. PubMed ID: 37295023
[TBL] [Abstract][Full Text] [Related]
10. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.
Matsui Y; Yasumatsu I; Asahi T; Kitamura T; Kanai K; Ubukata O; Hayasaka H; Takaishi S; Hanzawa H; Katakura S
Bioorg Med Chem; 2017 Jul; 25(13):3540-3546. PubMed ID: 28511909
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and structural insights into how amino acids regulate pyruvate kinase muscle isoform 2.
Nandi S; Dey M
J Biol Chem; 2020 Apr; 295(16):5390-5403. PubMed ID: 32144209
[TBL] [Abstract][Full Text] [Related]
12. Pyruvate kinase: Function, regulation and role in cancer.
Israelsen WJ; Vander Heiden MG
Semin Cell Dev Biol; 2015 Jul; 43():43-51. PubMed ID: 26277545
[TBL] [Abstract][Full Text] [Related]
13. Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity.
Chen C; Wang T; Wu F; Huang W; He G; Ouyang L; Xiang M; Peng C; Jiang Q
Drug Des Devel Ther; 2014; 8():1195-210. PubMed ID: 25214764
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform.
Ning X; Qi H; Li R; Jin Y; McNutt MA; Yin Y
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):126-129. PubMed ID: 29185365
[TBL] [Abstract][Full Text] [Related]
15. A novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia.
Kim DJ; Park YS; Kim ND; Min SH; You YM; Jung Y; Koo H; Noh H; Kim JA; Park KC; Yeom YI
Mol Cells; 2015 Apr; 38(4):373-9. PubMed ID: 25813626
[TBL] [Abstract][Full Text] [Related]
16. Pyruvate kinase M knockdown-induced signaling via AMP-activated protein kinase promotes mitochondrial biogenesis, autophagy, and cancer cell survival.
Prakasam G; Singh RK; Iqbal MA; Saini SK; Tiku AB; Bamezai RNK
J Biol Chem; 2017 Sep; 292(37):15561-15576. PubMed ID: 28778925
[TBL] [Abstract][Full Text] [Related]
17. Roadmap to Pyruvate Kinase M2 Modulation - A Computational Chronicle.
Kapoor S; Chatterjee DR; Chowdhury MG; Das R; Shard A
Curr Drug Targets; 2023; 24(6):464-483. PubMed ID: 36998144
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
Boxer MB; Jiang JK; Vander Heiden MG; Shen M; Skoumbourdis AP; Southall N; Veith H; Leister W; Austin CP; Park HW; Inglese J; Cantley LC; Auld DS; Thomas CJ
J Med Chem; 2010 Feb; 53(3):1048-55. PubMed ID: 20017496
[TBL] [Abstract][Full Text] [Related]
19. Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators.
Li R; Ning X; Zhou S; Lin Z; Wu X; Chen H; Bai X; Wang X; Ge Z; Li R; Yin Y
Eur J Med Chem; 2018 Jan; 143():48-65. PubMed ID: 29172082
[TBL] [Abstract][Full Text] [Related]
20. Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment.
Sarfraz I; Rasul A; Jabeen F; Sultana T; Adem Ş
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
